Login | New Member? Signup Free
ChangeDetect » News

Cytrx Reaches Patient Enrollment Target In Global Phase 2b Clinical Trial With Tamibarotene As First-line Treatment

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced that enrollment of 140 evaluable patients has been completed in the Company’s global Phase 2b clinical trial with its oral retinoid compound tamibarotene in combination with chemotherapeutic agents as a first-line treatment for patients with advanced non-small-cell lung cancer .

Tags: , , , , , , , , , , , , , ,